LF
INKT icon

Longbow Finance’s MiNK Therapeutics INKT Stock Holding History

Longbow Finance’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$176K Hold
16,667
– – 0.03% 55
2025
Q4 		$186K Hold
16,667
– – 0.03% 61
2025
Q3 		$233K Hold
16,667
– – 0.02% 68
2025
Q2 		$123K Hold
16,667
– – 0.01% 70
2025
Q1 		$144K Hold
16,667
– – 0.02% 79
2024
Q4 		$116K Hold
16,667
– – 0.01% 71
2024
Q3 		$125K Hold
16,667
– – 0.01% 86
2024
Q2 		$158K Hold
16,667
– – 0.02% 84
2024
Q1 		$151K Hold
16,667
– – 0.02% 83
2023
Q4 		$178K Buy
+16,667
New +$174K 0.02% 62
2023
Q2 		– Sell
-16,667
Closed -$316K – 62
2023
Q1 		$316K Hold
16,667
– – 0.04% 59
2022
Q4 		$435K Buy
+16,667
New +$391K 0.06% 56

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Longbow Finance's INKT Position: Q1 2026 in Review

Longbow Finance held its MiNK Therapeutics (INKT) position steady in Q1 2026 at 16,667 shares worth $176K. The position accounts for 0.03% of the portfolio, ranked #55.

Longbow Finance first reported a position in INKT in Q4 2022 and has held it in 12 quarters since. The position peaked at $435K in Q4 2022. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Longbow Finance held 16,667 shares of MiNK Therapeutics worth $176K as of Q1 2026.
  • Longbow Finance left its MiNK Therapeutics share count unchanged in Q1 2026.
  • MiNK Therapeutics made up 0.03% of Longbow Finance's portfolio in Q1 2026, its #55 holding.
  • Longbow Finance first reported a position in MiNK Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • Longbow Finance's MiNK Therapeutics position peaked at $435K in Q4 2022.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Longbow Finance's 13F filing for Q1 2026, filed 12 May 2026.